Blueprint Medicines at ENA 2026
Nov 18–20, 2026 Barcelona, Spain ~1.5k attendees Website
Blueprint Medicines brings 2 presentations to ENA 2026 in Barcelona. Its posters centre on SAR449336, an oral pan-KRAS inhibitor. The work shows it sparing HRAS and NRAS while staying broadly active in biochemical and cell assays and across KRAS-driven preclinical tumor models.
| Organization | ENA 2026 Attendance |
|---|---|
Blueprint Medicines Cambridge, MA | |
Precision medicine company developing kinase and KRAS inhibitors; owned by Sanofi. | Poster Thu Nov 19 9:30–10am 1–3pm 4:30–5pm Poster Thu Nov 19 9:30–10am 1–3pm 4:30–5pm |
Instantly find 20 buyers from Blueprint Medicines
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Not affiliated with or endorsed by EORTC, the NCI or the AACR. Submit a correction